Cyclacel Pharmaceuticals, Inc. also files under BGMS, XCYT; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nov 12, 2025 | Kiu Cu Seng | Chief Financial Officer, Director | Grant(A) | 200K | $1.40 | $280K |
| Nov 12, 2025 | Doris Wong Sing Ee | Chief Executive Officer, Director, 10% Owner | Grant(A) | 300K | $1.40 | $420K |
| Nov 5, 2025 | Yap Kim Choy | 10% Owner | Other(J) | 468K | — | $0 |
| Nov 5, 2025 | Yap Kim Choy | 10% Owner | Other(J) | 218K | — | $0 |
| Nov 5, 2025 | Ong Yee Lung | 10% Owner | Other(J) | 32K | — | $0 |
| Nov 5, 2025 | Ong Yee Lung | 10% Owner | Other(J) | 468K | — | $0 |
| Nov 5, 2025 | Kua Khai Loon | 10% Owner | Other(J) | 218K | — | $0 |
| Nov 5, 2025 | Yap Kim Choy | 10% Owner | Other(J) | 32K | — | $0 |
| Nov 5, 2025 | Kua Khai Loon | 10% Owner | Other(J) | 32K | — | $0 |
| Nov 5, 2025 | Ong Yee Lung | 10% Owner | Other(J) | 218K | — | $0 |
| Nov 5, 2025 | Kua Khai Loon | 10% Owner | Other(J) | 218K | — | $0 |
| Nov 5, 2025 | Yap Kim Choy | 10% Owner | Sell(S) | 29K | $1.70 | $49K |
| Nov 5, 2025 | Yap Kim Choy | 10% Owner | Other(J) | 218K | — | $0 |
| Nov 5, 2025 | Ong Yee Lung | 10% Owner | Other(J) | 218K | — | $0 |
| Nov 5, 2025 | Kua Khai Loon | 10% Owner | Other(J) | 468K | — | $0 |
| Oct 30, 2025 | Yap Kim Choy | 10% Owner | Sell(S) | 112K | $1.81 | $203K |
| Oct 30, 2025 | Kua Khai Loon | 10% Owner | Sell(S) | 242K | $1.80 | $436K |
| Oct 30, 2025 | Ong Yee Lung | 10% Owner | Sell(S) | 249K | $1.80 | $448K |
| Oct 29, 2025 | Yap Kim Choy | 10% Owner | Sell(S) | 111K | $1.83 | $203K |
| Oct 28, 2025 | Yap Kim Choy | 10% Owner | Sell(S) | 13K | $1.83 | $24K |
| Oct 27, 2025 | Yap Kim Choy | 10% Owner | Sell(S) | 120K | $2.12 | $255K |
| Oct 24, 2025 | Yap Kim Choy | 10% Owner | Sell(S) | 20K | $1.90 | $37K |
| Oct 24, 2025 | Ong Yee Lung | 10% Owner | Sell(S) | 20K | $1.99 | $40K |
| Oct 21, 2025 | FITTERS Diversified Berhad | 10% Owner | Sell(S) | 92K | $3.01 | $278K |
| Oct 20, 2025 | FITTERS Diversified Berhad | 10% Owner | Sell(S) | 108K | $3.09 | $334K |
| Oct 16, 2025 | Kua Khai Loon | 10% Owner | Sell(S) | 88K | $4.22 | $372K |
| Oct 16, 2025 | FITTERS Diversified Berhad | 10% Owner | Sell(S) | 26K | $5.50 | $143K |
| Oct 15, 2025 | Kua Khai Loon | 10% Owner | Sell(S) | 7K | $5.66 | $42K |
| Oct 14, 2025 | Ong Yee Lung | 10% Owner | Sell(S) | 136K | $6.00 | $815K |
| Oct 10, 2025 | FITTERS Diversified Berhad | 10% Owner | Sell(S) | 51K | $5.26 | $270K |
| Oct 8, 2025 | FITTERS Diversified Berhad | 10% Owner | Sell(S) | 142K | $5.29 | $751K |
| Sep 16, 2025 | Kua Khai Loon | 10% Owner | Sell(S) | 25K | $5.13 | $128K |
| Sep 12, 2025 | Kua Khai Loon | 10% Owner | Sell(S) | 22K | $6.22 | $138K |
| Sep 5, 2025 | Kua Khai Loon | 10% Owner | Sell(S) | 19K | $7.01 | $134K |
| Sep 4, 2025 | Yap Kim Choy | 10% Owner | Other(J) | 186K | — | $0 |
| Sep 4, 2025 | Kua Khai Loon | 10% Owner | Other(J) | 186K | — | — |
| Sep 4, 2025 | Ong Yee Lung | 10% Owner | Other(J) | 186K | — | $0 |
| Sep 4, 2025 | Ong Yee Lung | 10% Owner | Other(J) | 186K | — | — |
| Sep 4, 2025 | Yap Kim Choy | 10% Owner | Other(J) | 186K | — | — |
| Sep 4, 2025 | Kua Khai Loon | 10% Owner | Other(J) | 186K | — | $0 |
| Jul 30, 2025 | Lazar David E. | 10% Owner | Sell(S) | 7K | $12.36 | $83K |
| Feb 26, 2025 | Lazar David E. | Interim CEO, 10% Owner | Option exercise(M) | 1.0M | — | — |
| Feb 26, 2025 | Lazar David E. | Interim CEO, 10% Owner | Option exercise(M) | 1.7M | — | — |
| Feb 26, 2025 | Lazar David E. | Interim CEO, 10% Owner | Option exercise(M) | 192.0M | — | — |
| Feb 26, 2025 | Lazar David E. | Interim CEO, 10% Owner | Option exercise(M) | 2.6M | — | — |
| Feb 26, 2025 | Lazar David E. | Interim CEO, 10% Owner | Sell(S) | 194.6M | $0.03 | $5.8M |
| Feb 26, 2025 | Ben-Tzvi Avraham | Director | Grant(A) | 700K | — | $0 |
| Feb 26, 2025 | Natan David | Director | Grant(A) | 700K | — | $0 |
| Feb 6, 2025 | Lazar David E. | Interim CEO, 10% Owner | Grant(A) | 2.1M | — | — |
| Jan 2, 2025 | Natan David | Director | Grant(A) | 100K | — | — |
| Jan 29, 2024 | Schwartz Brian | Interim Chief Medical Officer, Director | Grant(A) | 13K | — | $0 |
| Jan 29, 2024 | Schwartz Brian | Interim Chief Medical Officer, Director | Grant(A) | 13K | — | $0 |
| Dec 21, 2023 | McBarron Paul | See Remarks, Director | Buy(P) | 2K | — | $0 |
| Dec 21, 2023 | McBarron Paul | See Remarks, Director | Buy(P) | 2K | $3.32 | $6K |
| Dec 21, 2023 | Rombotis Spiro George | President and CEO, Director | Buy(P) | 6K | — | $0 |
| Dec 21, 2023 | Rombotis Spiro George | President and CEO, Director | Buy(P) | 6K | $3.32 | $20K |
| Jun 30, 2023 | Spiegel Robert J. | Director | Grant(A) | 42K | — | $0 |
| Jun 30, 2023 | Rombotis Spiro George | President and CEO, Director | Grant(A) | 110K | — | $0 |
| Jun 30, 2023 | Barker Sam L | Director | Grant(A) | 42K | — | $0 |
| Jun 30, 2023 | Barker Sam L | Director | Grant(A) | 21K | — | $0 |
| Jun 30, 2023 | Spiegel Robert J. | Director | Grant(A) | 21K | — | $0 |
| Jun 30, 2023 | McBarron Paul | See Remarks, Director | Grant(A) | 70K | — | $0 |
| Jun 30, 2023 | Kirschbaum Mark | Chief Medical Officer | Grant(A) | 70K | — | $0 |
| Jun 30, 2023 | Walker Karin L | Director | Grant(A) | 21K | — | $0 |
| Jun 30, 2023 | Ferguson Kenneth M. | Director | Grant(A) | 42K | — | $0 |
| Jun 30, 2023 | Ferguson Kenneth M. | Director | Grant(A) | 21K | — | $0 |
| Jun 30, 2023 | Henney Christopher S | Director | Grant(A) | 42K | — | $0 |
| Jun 30, 2023 | Henney Christopher S | Director | Grant(A) | 21K | — | $0 |
| Jun 30, 2023 | Schwartz Brian | Director | Grant(A) | 42K | — | $0 |
| Jun 30, 2023 | Walker Karin L | Director | Grant(A) | 42K | — | $0 |
| Jun 30, 2023 | Schwartz Brian | Director | Grant(A) | 21K | — | $0 |
| Jan 31, 2023 | Rombotis Spiro George | President and CEO, Director | Grant(A) | 58K | — | $0 |
| Jan 31, 2023 | McBarron Paul | See Remarks, Director | Grant(A) | 31K | — | $0 |
| Jan 31, 2023 | Kirschbaum Mark | Chief Medical Officer | Grant(A) | 31K | — | $0 |
| Jun 14, 2022 | Spiegel Robert J. | Director | Grant(A) | 32K | — | $0 |
| Jun 14, 2022 | Ferguson Kenneth M. | Director | Grant(A) | 24K | — | $0 |
| Jun 14, 2022 | Walker Karin L | Director | Grant(A) | 32K | — | $0 |
| Jun 14, 2022 | Walker Karin L | Director | Grant(A) | 16K | — | $0 |
| Jun 14, 2022 | Spiegel Robert J. | Director | Grant(A) | 16K | — | $0 |
| Jun 14, 2022 | Sems Lloyd | Director | Grant(A) | 32K | — | $0 |
| Jun 14, 2022 | Sems Lloyd | Director | Grant(A) | 16K | — | $0 |
| Jun 14, 2022 | Schwartz Brian | Director | Grant(A) | 32K | — | $0 |
| Jun 14, 2022 | Schwartz Brian | Director | Grant(A) | 16K | — | $0 |
| Jun 14, 2022 | Henney Christopher S | Director | Grant(A) | 32K | — | $0 |
| Jun 14, 2022 | Henney Christopher S | Director | Grant(A) | 16K | — | $0 |
| Jun 14, 2022 | Barker Sam L | Director | Grant(A) | 32K | — | $0 |
| Jun 14, 2022 | Barker Sam L | Director | Grant(A) | 16K | — | $0 |
| Jun 14, 2022 | Ferguson Kenneth M. | Director | Grant(A) | 47K | — | $0 |
| Dec 13, 2021 | Rombotis Spiro George | President and CEO, Director | Grant(A) | 190K | — | $0 |
| Dec 13, 2021 | McBarron Paul | See Remarks, Director | Grant(A) | 100K | — | $0 |
| Dec 13, 2021 | Kirschbaum Mark | Chief Medical Officer | Grant(A) | 100K | — | $0 |
| Nov 30, 2021 | Barker Sam L | Director | Sell(S) | 12 | $3.57 | $43 |
| Nov 18, 2021 | Rombotis Spiro George | President and CEO, Director | Buy(P) | 4K | $4.50 | $18K |
| Aug 24, 2021 | Barker Sam L | Director | Buy(P) | 1K | $5.00 | $5K |
| Jun 15, 2021 | Schwartz Brian | Director | Grant(A) | 2K | — | $0 |
| Jun 15, 2021 | Schwartz Brian | Director | Grant(A) | 5K | — | $0 |
| Jun 15, 2021 | Schwartz Brian | Director | Grant(A) | 1K | — | $0 |
| Jun 15, 2021 | Schwartz Brian | Director | Grant(A) | 2K | — | $0 |
| Jun 15, 2021 | Walker Karin L | Director | Grant(A) | 2K | — | $0 |
| Jun 15, 2021 | Walker Karin L | Director | Grant(A) | 1K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Cyclacel Pharmaceuticals, Inc., SEC CIK 0001130166. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under CYCC and shows every filing by that issuer (also filed as BGMS, XCYT).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-15. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for CYCC